Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONARCH
NCT06108219Phase 2Completed
- Sponsor
- Corcept Therapeutics
- Start
- Oct 2023
- Primary completion
- Feb 2026
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of miricorilant in Nonalcoholic steatohepatitis (NASH), sponsored by Corcept Therapeutics. Started Oct 2023; status: completed.
02
Drugs
miricorilant
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06108219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108219.